natgillin/translations-raw huggingface dataset:
60 x 1 tablet (unit
60 x 1 tableta
60 x 1 tablet (unit dose)
60 x 1 tableta (jedinica doze)
60 x 1 tablet (unit dose)
60 x 1 tableta (jedinična doza)
60 x 1 tablet (unit dose)
60 x 1 tableta (jedinično pakiranje)
60 x 1 tablets
tableta
60 x 1 tablets (unit dose)
60 x 1 tableta (jedinična doza)
60 x 1 tablets (unit dose)
60 x 1 tableta (jedinične doze)
60 x 1 tablets (unit dose)
60 x 1 tableta (unit dose)
60 years and above 21 Days After
60 godina i više 21 dan kasnije
60 µg
60µg
60% (25) (p=0.013b)
60% (25) (p=0,013b)
60% of subjects had underlying ALS and 40% of subjects had underlying MS.
Od tih ispitanika, 60% imalo je ALS a 40% MS.
60, 90, 100 and 105 film-coated tablets and in perforated blister packs of 50 x 1 film-coated tablet (unit dose).
40,50,60, 90, 100 i 105 filmom obloženih tableta te u perforiranim blisterima od 50 x 1 filmom obložena tableta (jedinična doza).
60-322 Poznan Poland
60-322 Poznan Poljska
60-64 Years
60-64-godišnjaci
60-64 Years
60-64-godišnjake
60-64 Years N=359-404
60-64- godišnjaci N=359-404
60-64 Years N=367-402
60-64- godišnjaci N=367-402
60-75 minutes (ml/hr)
60-75 minuta (ml/sat)
60.2 months (NR)
60,2 mjeseca
60.4% of patients treated with Xultophy reached a target of HbA1c <7% without confirmed hypoglycaemic episodes after 26 weeks of treatment.
60,4% bolesnika liječenih lijekom Xultophy dostiglo je ciljnu vrijednost HbA1c <7% bez potvrđenih epizoda hipoglikemije nakon 26 tjedana liječenja.
600 IU (44 g)/vial
600 IU (44 μg)/bočica
600 IU*** human von Willebrand factor** (VWF).
600 IU*** ljudskog von Willebrandova faktora** (VWF)
600 IU/ml after reconstitution).
600 IU/ml nakon pripreme).
600 mg (30 ml) once daily
600 mg (30 ml) jedanput na dan
600 mg (600 kg bodyweight)
600 mg (600 kg tjelesne težine)
600 mg at bedtime
600 mg
600 mg at bedtime
600 mg navečer prije spavanja (N=282)
600 mg at week 3; then 600 mg every 2 weeks
600 mg u 3. tjednu; potom 600 mg svaka 2 tjedna
600 mg once daily
600 mg jedanput dnevno
600 mg once daily
600 mg jedanput na dan
600 mg once daily
600 mg jednom dnevno
600 mg once every 48 hours
600 mg jedanput svakih 48 sati
600 mg once every 72 hours
600 mg jedanput svaka 72 sata
600 mg once every 96 hours
600 mg jedanput svakih 96 sati
600 mg or 8 mg/kg every 8 weeks
600 mg ili 8 mg/kg svakih 8 tjedana
600 mg prednisolone
600 mg prednizolon
600 mg prednisolone (18 g sachet)
600 mg prednizolon (18 g vrećica)
600 mg PREZISTA/100 mg ritonavir twice daily
600 mg PREZISTA/100 mg ritonavir, dva puta na dan
600 mg QD
600 mg 1x/ dan
600 mg QD
600 mg 1x/dan
600 mg QD
Rifampicin 600 mg 1x/dan
600 mg to be taken as 1 capsule of 400 mg plus 2 capsules of 100 mg once a day.
600 mg se uzima kao 1 kapsula od 400 mg plus 2 kapsule od 100 mg jednom na dan.
600 mg to be taken as 1 tablet of 400 mg plus 2 tablets of 100 mg once a day.
600 mg se uzima kao 1 tableta od 400 mg plus 2 tablete od 100 mg jednom na dan.
600 mg to be taken as 6 tablets once a day.
600 mg se uzima kao 6 tablete jednom na dan.
600 mg to be taken as one tablet of 400 mg plus 2 tablets of 100 mg once a day.
600 mg se uzima kao jedna tableta od 400 mg i 2 tablete od 100 mg jednom na dan.
600 mg twice
400 mg
600 mg weekly x 1
600 mg tjedno x 1
600 mg weekly x 2
600 mg tjedno x 2
600 mg/ m2 intravenous 22 hr
m2 intravenski 22 sata
600 micrograms fentanyl (as citrate)
600 mikrograma fentanila (u obliku fentanilcitrata)
600 milligram PREZISTA + 100 milligram ritonavir twice a day
600 miligrama lijeka PREZISTA + 100 miligrama ritonavira, dva puta na dan
600 milligram PREZISTA together with 100 milligram ritonavir twice daily.
600 miligrama lijeka PREZISTA zajedno sa 100 miligrama ritonavira dva puta na dan.
600 q12h
12h
600/100 mg twice daily
600/100 mg dva puta
600/300 mg once daily
400 mg jedanput na dan
6013329, Packard Instruments, USA or equivalent).
6013329, koji proizvodi Packard Instruments, SAD, ili ekvivalentan).
60x1 film-coated tablets in perforated unit dose blisters.
60x1 filmom obloženih tableta u perforiranim blisterima djeljivima na jedinične doze.
60x1 hard capsules.
60 x 1 tvrda kapsula.
60x1 tablets
60x1 tableta
60x1 tablets (unit dose)
60x1 tableta (jedinična doza)
60×1 capsule
60×1 kapsula
61 to 70 years
61 do 70 godina
61-70 years
61-70 godina
61.7 (9.0)
afinamid
61118 Bad Vilbel Germany
D-61118 Bad Vilbel Njemačka
6167 RD Geleen Netherlands
6167 RD Geleen Nizozemska
61700 Brno Czech Republic
61700 Brno Češka Republika
62.9%
indeksu
62010 Montecosaro (MC) – Italy
62010 Montecosaro (MC) – Italija
6221 CB Maastricht The Netherlands
6221 CB Maastricht Holandija
625 micrograms of romiplostim.
625 mikrograma rimoplostima.
625 micrograms of romiplostim.
625 mikrograma romiplostima.
6250 Kundl Austria
6250 Kundl Austrija
62660 Beuvry France
62660 Beuvry Francuska
63 film-coated tablets
63 filmom obložene tablete
63 micrograms, choose orange pen
63 mikrograma, izaberite narančastu brizgalicu
63 micrograms, choose orange syringe
63 mikrograma, izaberite narančastu štrcaljku
63-81 High Street Rickmansworth Hertfordshire WD3 1EQ United Kingdom
63-81–81 High Street Rickmansworth Hertfordshire WD3 1 1EQ Ujedinjeno Kraljevstvo
63.9% to 95.5%
63,9 % do 95,5
637377 Singapore Singapore
637377 Singapur Singapur
637394 Singapore Singapore
637394 Singapur Singapur
63800 Cournon d’Auvergne France
63800 Cournon d’Auvergne Francuska
63800 Courron d‘Auvergne France
63800 Courron d‘Auvergne Francuska
63963 Clermont-Ferrand Cedex 9 France
63963 Clermont-Ferrand Cedex 9 Francuska
63–81 High Street Rickmansworth Hertfordshire WD3 1EQ United Kingdom
63–81 High Street Rickmansworth Hertfordshire WD3 1 1EQ Ujedinjeno Kraljevstvo
63–81 High Street Rickmansworth Hertfordshire WD3 1EQ United Kingdom
63–81 High Street Rickmansworth Hertfordshire WD3 1EQ Ujedinjeno Kraljevstvo
64% subjects participating in ENABLE 1 and ENABLE 2 were genotype 1 f Post-hoc analyses
64% ispitanika koji su sudjelovali u ENABLE 1 i ENABLE 2 imali su genotip 1 f post-hoc analize
64.1% (41/64)
Virusni proboj
64.4 (39.4%) ng/ml, respectively.
3324 (41,2%) ng·h/ml i Cmin od 64,4 (39,4%) ng/ml.
64.9 (45.7 to
64,9 (45,7 do
6400 mg (single dose): One case reported in the literature of one patient who experienced nausea, vomiting, abdominal pain, pyrexia, facial swelling, decreased neutrophil count, increased transaminases.
6400 mg (jednokratna doza): u literaturi je zabilježen slučaj jednog bolesnika s mučninom, povraćanjem, bolovima u trbuhu, vrućicom, oticanjem lica, smanjenim brojem neutrofila, povišenjem vrijednosti transaminaza.
64293 Darmstadt Germany
64293 Darmstadt Njemačka
645 41 Strängnäs Sweden
645 41 Strängnäs Švedska
64Cu is a beta emitter.
64Cu je beta emiter.
64Cu-labelled medicinal products should not be used in children and adolescents up to 18 years.
64Cu-obilježeni lijekovi ne smiju se koristiti u djece i adolescenata do 18 godina starosti.
65 or older: Take one 5 mg capsule
65 godina ili stariji: uzeti jednu kapsulu od 5 mg
65 years.
Oštećenje bubrega
65 ≤ and < 75
65 ≤ i < 75
65%; P < .0001
65%; P < 0,0001
650 units*.
650 jedinica*.
6545 CG Nijmegen Netherlands
6545 CG Nijmegen Nizozemska
6545 CG Nijmegen, The Netherlands
6545 CG Nijmegen, Nizozemska
65926 Frankfurt am Main Germany
65926 Frankfurt na Majni Njemačka
66 micrograms (18 million IU)/1.5 mL
66 mikrograma (18 milijuna IU)/1,5 ml
66% of patients were receiving vitamin D sterols at study entry, and > 90% were receiving phosphate binders.
Na početku studije 66 % bolesnika primalo je sterole vitamina D, a > 90 % bolesnika primalo je tvari koje vežu fosfate.
66%; P < .0001
66%; P < 0,0001
66.2% of Fortacin-treated subjects and 18.8% of placebo-treated subjects achieved a mean IELT
66,2 % skupine liječene Fortacin i 18,8% liječenih placebom postiglo je IELT
66.6 (42.0 to -)
66,6 (42,0 do -)
660 MedImmune Court / 633 Research Court, Frederick, Maryland, USA
660 MedImmune Court / 633 Research Court, Frederick, Maryland, SAD
67 (20.9)
gingivitis
67 mg lactose per tablet
67 mg laktoze po tableti
67% (12 of 18) of Strimvelis treated patients had either autoimmune antibodies or other manifestations (e.g. autoimmune thrombocytopenia, autoimmune aplastic anaemia, autoimmune hepatitis and Guillain-Barré syndrome) (see section 4.8).
Šezdeset i sedam posto (12 od 18) bolesnika liječenih lijekom Strimvelis imalo je ili autoimuna protutijela ili neke druge manifestacije (npr. autoimunu trombocitopeniju, autoimunu aplastičnu anemiju, autoimuni hepatitis i Guillain-Barréov sindrom) (vidjeti dio 4.8).
67%; P < .0001
67%; P < 0,0001
67.2 micrograms
67,2 mikrograma
67.6%
vi parcijalni
67061 Ludwigshafen GERMANY
67061 Ludwigshafen NJEMAČKA
67061 Ludwigshafen Germany
67061 Ludwigshafen, Njemačka
675 mg (6.8 ml)b PREZISTA/100 mg (1.2 ml) ritonavir once daily
675 mg (6,8 ml)b PREZISTA/100 mg (1,2 ml) ritonavir jedanput na dan
675 milligram (6.8 milliliter)
675 miligrama (6,8 mililitara)
67801 Blansko Czech Republic
67801 Blansko Češka Republika
68.0 mg/tablet
68.0 mg/tableta
683 23 Ivanovice na Hané, CZECH REPUBLIC
683 23 Ivanovice na Hané, ČEŠKA REPUBLIKA
683 23, Ivanovice na Hané, CZECH REPUBLIC
683 23 Ivanovice na Hané, ČEŠKA REPUBLIKA
69 % of the patients with UC had a SCCAI score ≤2 and 31 % a SCCAI score of 3.
69 % bolesnika s UC-om imalo je rezultat ≤ 2 prema indeksu SCCAI, a 31 % rezultat 3.
69 (83%)
romiplostim (n = 83)
69%
Placebo
69% (11/16)
T12(DS)/PR
69.5 (58.6 to -)
69,5 (58,6 do -)
69.6% to 98.8%
69,6 % do 98,8
69007 Lyon France
69007 Lyon Francuska
691 days (95% CI 638;754) with a hazard ratio of 0.61 (95% CI 0.56; 0.66).
17,0) s omjerom hazarda od 0,61 (95% CI 0,56; 0,66).
69115 HEIDELBERG GERMANY
69115 HEIDELBERG NJEMAČKA
69342 LYON CEDEX 07 FRANCE
69342 LYON CEDEX 07 FRANCUSKA
69800 Saint Priest FRANCE
69800 Saint Priest Francuska
69800 Saint Priest FRANCE
F-69800 Saint Priest FRANCUSKA
6c Prime the IV line according to the manufacturer’s guidelines.
6c Pripremite intravensku infuzijsku liniju (izbacite zrak) sukladno uputama proizvođača.
6In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2 – 3 kg over one year.
6 U ispitivanjima kontroliranima aktivnim usporednim lijekom, prosječno povećanje tjelesne težine tijekom monoterapije pioglitazonom iznosilo je 2–3 kg tijekom jedne godine.
6In clinical trials, the incidence of Parkinsonism and dystonia in olanzapine-treated patients was numerically higher, but not statistically significantly different from placebo.
6 U kliničkim ispitivanjima incidencija parkinsonizma i distonije u bolesnika liječenih olanzapinom bila je brojčano veća, ali nije bila statistički znatno različita u odnosu na placebo.
6MWD (metres, median change)
6MWD (metri, medijan vrijednosti promjene)
6MWD Results in Patients with a Baseline 6MWD < 350 meters.
Rezultati udaljenosti prijeđene u 6 minuta u bolesnika s početnom vrijednosti <350 metara
6Time to Disease Progression: interval from the first infusion to disease progression.
6Vrijeme do napredovanja bolesti: razdoblje od prve infuzije do napredovanja bolesti.
6x1 capsules + 1 inhaler 10x1 capsules + 1 inhaler 12x1 capsules + 1 inhaler 30x1 capsules + 1 inhaler
6x1 kapsula + 1 inhalator 10x1 kapsula + 1 inhalator 12x1 kapsula + 1 inhalator 30x1 kapsula + 1 inhalator
6x1 capsules + 1 inhaler.
6x1 kapsula + 1 inhalator.
6–mercaptopurine causes embryolethality and severe teratogenic effects in the mouse, rat, hamster and rabbit at doses that are non-toxic to the mother.
6–merkaptopurin uzrokuje smrt embrija i teške teratogene učinke na mišu, štakoru, hrčku i kuniću u dozama koje nisu toksične za majku.
6–mercaptopurine displays diurnal variation in pharmacokinetics and efficacy.
6–merkaptopurin pokazuje diurnalne varijacije u farmakokinetici i djelotvornosti.
6–mercaptopurine has been identified in the colostrum and breast-milk of women receiving azathioprine treatment and thus women receiving Xaluprine should not breast-feed.
6–merkaptopurin je nađen u kolostrumu i majčinom mlijeku žena koje primaju azatioprin pa stoga žene koje primaju Xaluprine ne smiju dojiti.
6–mercaptopurine is also subject to S-methylation by the enzyme thiopurine S- methyltransferase (TPMT), yielding methylmercaptopurine, which is inactive.
6–merkaptopurin također prolazi S-metilaciju pomoću tiopurin S-metiltransferaze (TPMT) kojom nastaje metilmerkaptopurin, koji je inaktivan.
6–mercaptopurine is an inactive pro-drug which acts as a purine antagonist but requires cellular uptake and intracellular anabolism to thioguanine nucleotides for cytotoxicity.
6–merkaptopurin je neaktivni predlijek koji djeluje kao antagonist purina, ali mu je za citotoksični učinak potreban unos u stanicu i unutarstanična dogradnja do tiogvaninskih nukleotida.
6–mercaptopurine is hepatotoxic in animals and man.
6–merkaptopurin je hepatotoksičan u životinja i ljudi.
6–mercaptopurine is metabolised by the polymorphic TPMT enzyme.
6–merkaptopurin se metabolizira putem polimorfnog enzima TPMT.
6–mercaptopurine, in common with other antimetabolites, is mutagenic and causes chromosomal aberrations in vitro and in vivo in mice and rats.
6-merkaptopurin, kao i drugi antimetaboliti, mutagen je i uzrokuje kromosomske aberacije in vitro i in vivo u miševa i štakora.
6−<12 years
6 − <12 godina
7 & 10 TABLET PVC-PCTFE/ALU BLISTER (for white and clear blister)
PVC-PCTFE/AL BLISTER SA 7 i 10 TABLETA (za bijeli i prozirni blister)
7 (2.1)
artralgija
7 Allopurinol
7 Alopurinol
7 Based on post-marketing experience
7 na temelju iskustva nakon stavljanja lijeka u promet
7 capsule cards (one card for each day of the week).
7 kartica s kapsulama (jedna kartica za svaki dan u tjednu).
7 coated tablets
7 obloženih tableta
7 days of uninterrupted ‘white active tablet’-taking are required to attain adequate suppression of the hypothalamic-pituitary-ovarian-axis.
Potrebno je 7 dana neprekidnog uzimanja 'bijele tablete s djelatnim tvarima' kako bi se postigla odgovarajuća supresija osi hipotalamus-hipofiza-jajnik.
7 deaths (1.5%; 14.6/1000 person-years): 2 cases of status epilepticus, of which one was related to severe weight loss (10% within 3 months) in an underweight subject and subsequent failure to take medication; 1 case of head injury/haematoma, and 4 deaths in subjects with pre-existing functional neurological deficits for various causes (2 cases of pneumonia-induced sepsis/organ failure, 1 SUDEP and 1 head injury).
14,6/1000 osoba-godina), i to 2 slučaja statusa epileptikusa od kojih je jedan bio povezan s teškim gubitkom težine (10% unutar 3 mjeseca) u jednog ispitanika s tjelesnom težinom manjom od prosječne i posljedičnom nemogućnošću uzimanja lijeka; 1 slučaj ozljede glave/hematoma i 4 smrtna slučaja u ispitanika s prethodno postojećim funkcionalnim neurološkim deficitima zbog različitih uzroka (2 slučaja sepse/zatajenja organa prouzročenih upalom pluća, 1 slučaj iznenadne neobjašnjive smrti bolesnika s epilepsijom (SUDEP) i 1 ozljeda glave).
7 December 2011
7. prosinca 2011.
7 film-coated tablets 10 film-coated tablets 20 film-coated tablets 30 film-coated tablets 50 film-coated tablets 90 film-coated tablets 100 film-coated tablets
7 filmom obloženih tableta 10 filmom obloženih tableta 20 filmom obloženih tableta 30 filmom obloženih tableta 50 filmom obloženih tableta 90 filmom obloženih tableta 100 filmom obloženih tableta
7 Film-coated tablets Ebixa 10 mg
7 Ebixa 10 mg filmom obloženih tableta
7 Film-coated tablets Ebixa 15 mg
7 Ebixa 15 mg filmom obloženih tableta
7 Film-coated tablets Ebixa 20 mg
7 Ebixa 20 mg filmom obloženih tableta
7 Film-coated tablets Ebixa 5 mg
7 Ebixa 5 mg filmom obloženih tableta
7 film-coated tablets of Ebixa 10 mg 7 film-coated tablets of Ebixa 15 mg 7 film-coated tablets of Ebixa 20 mg
7 Ebixa 10 mg filmom obloženih tableta 7 Ebixa 15 mg filmom obloženih tableta 7 Ebixa 20 mg filmom obloženih tableta
7 film-coated tablets of Nemdatine 10 mg 7 film-coated tablets of Nemdatine 15 mg 7 film-coated tablets of Nemdatine 20 mg
7 Nemdatine 10 mg filmom obloženih tableta 7 Nemdatine 15 mg filmom obloženih tableta 7 Nemdatine 20 mg filmom obloženih tableta
7 film-coated tablets: EU/1/09/556/001 14 film-coated tablets: EU/1/09/556/002 28 film-coated tablets: EU/1/09/556/003 30 film-coated tablets: EU/1/09/556/004 50 film-coated tablets: EU/1/09/556/005 56 film-coated tablets: EU/1/09/556/006 60 film-coated tablets: EU/1/09/556/010 84 film-coated tablets: EU/1/09/556/007 90 film-coated tablets: EU/1/09/556/008 100 film-coated tablets: EU/1/09/556/009 112 film-coated tablets: EU/1/09/556/012
7 filmom obloženih tableta: EU/1/09/556/001 14 filmom obloženih tableta: EU/1/09/556/002 28 filmom obloženih tableta: EU/1/09/556/003 30 filmom obloženih tableta: EU/1/09/556/004 50 filmom obloženih tableta: EU/1/09/556/005 56 filmom obloženih tableta: EU/1/09/556/006 60 filmom obloženih tableta: EU/1/09/556/010 84 filmom obložene tablete: EU/1/09/556/007 90 filmom obloženih tableta: EU/1/09/556/008 100 filmom obloženih tableta: EU/1/09/556/009 112 filmom obloženih tableta: EU/1/09/556/012
7 film-coated tablets: EU/1/09/556/001 14 film-coated tablets: EU/1/09/556/002 28 film-coated tablets: EU/1/09/556/003 30 film-coated tablets: EU/1/09/556/004 50 film-coated tablets: EU/1/09/556/005 56 film-coated tablets: EU/1/09/556/006 60 film-coated tablets: EU/1/09/556/010 84 film-coated tablets: EU/1/09/556/007 90 film-coated tablets: EU/1/09/556/008 100 film-coated tablets: EU/1/09/556/009 112 film-coated tablets: EU/1/09/556/012 120 film-coated tablets: EU/1/09/556/011
7 filmom obloženih tableta: EU/1/09/556/001 14 filmom obloženih tableta: EU/1/09/556/002 28 filmom obloženih tableta: EU/1/09/556/003 30 filmom obloženih tableta: EU/1/09/556/004 50 filmom obloženih tableta: EU/1/09/556/005 56 filmom obloženih tableta: EU/1/09/556/006 60 filmom obloženih tableta: EU/1/09/556/010 84 filmom obložene tablete: EU/1/09/556/007 90 filmom obloženih tableta: EU/1/09/556/008 100 filmom obloženih tableta: EU/1/09/556/009 112 filmom obloženih tableta: EU/1/09/556/012 120 filmom obloženih tableta: EU/1/09/556/011
7 film-coated tablets: EU/1/09/558/001 14 film-coated tablets: EU/1/09/558/002 28 film-coated tablets: EU/1/09/558/003 30 film-coated tablets: EU/1/09/558/004 50 film-coated tablets: EU/1/09/558/005 56 film-coated tablets: EU/1/09/558/006 60 film-coated tablets: EU/1/09/558/007 84 film-coated tablets: EU/1/09/558/008 90 film-coated tablets: EU/1/09/558/009 100 film-coated tablets: EU/1/09/558/010
7 filmom obloženih tableta: EU/1/09/558/001 14 filmom obloženih tableta: EU/1/09/558/002 28 filmom obloženih tableta: EU/1/09/558/003 30 filmom obloženih tableta: EU/1/09/558/004 50 filmom obloženih tableta: EU/1/09/558/005 56 filmom obloženih tableta: EU/1/09/558/006 60 filmom obloženih tableta: EU/1/09/558/007 84 filmom obloženih tableta: EU/1/09/558/008 90 filmom obloženih tableta: EU/1/09/558/009 100 filmom obloženih tableta: EU/1/09/558/010
7 film-coated tablets: EU/1/09/559/001 14 film-coated tablets: EU/1/09/559/002 28 film-coated tablets: EU/1/09/559/003 30 film-coated tablets: EU/1/09/559/004 50 film-coated tablets: EU/1/09/559/005 56 film-coated tablets: EU/1/09/559/006 84 film-coated tablets: EU/1/09/559/007 90 film-coated tablets: EU/1/09/559/008 100 film-coated tablets: EU/1/09/559/009 30x1 film-coated tablets EU/1/09/559/010 50x1 film-coated tablets EU/1/09/559/011
7 filmom obloženih tableta: EU/1/09/559/001 14 filmom obloženih tableta: EU/1/09/559/002 28 filmom obloženih tableta: EU/1/09/559/003 30 filmom obloženih tableta: EU/1/09/559/004 50 filmom obloženih tableta: EU/1/09/559/005 56 filmom obloženih tableta: EU/1/09/559/006 84 filmom obloženih tableta: EU/1/09/559/007 90 filmom obloženih tableta: EU/1/09/559/008 100 filmom obloženih tableta: EU/1/09/559/009 30x1 filmom obloženih tableta EU/1/09/559/010 50x1 filmom obloženih tableta EU/1/09/559/011
7 Follow-up analysis was performed with a data cut-off date of 07 March 2014
7 Analiza nakon praćenja provedena je na temelju podataka prikupljenih do 7. ožujka 2014.
7 gastro-resistant tablets
7 želučanootpornih tableta
7 GRADUATED pre-filled syringes
7 KALIBRIRANIH napunjenih štrcaljki
7 hard capsules
7 tvrdih kapsula
7 hard gastro-resistant capsules 14 hard gastro-resistant capsules 28 hard gastro-resistant capsules 98 hard gastro-resistant capsules 7 x 1 hard gastro-resistant capsules 28 x 1 hard gastro-resistant capsules
7 tvrdih želučanootpornih kapsula 14 tvrdih želučanootpornih kapsula 28 tvrdih želučanootpornih kapsula 98 tvrdih želučanootpornih kapsula 7 x 1 tvrdih želučanootpornih kapsula 28 x 1 tvrdih želučanootpornih kapsula
7 hypodermic injection needle (27 gauge) 14 alcohol swabs.
7 igala za potkožnu primjenu (27 G) 14 blazinica natopljenih alkoholom.
7 Including fatalities (see section 4.4).
7 uključujući smrtne slučajeve (vidjeti dio 4.4).
7 injection needle (20 gauge)
7 igala za injekciju (20 G)
7 inner cartons).
7 unutarnjih kutija).
7 kg
Tjelesna
7 Mean HbA1c change is the difference between the saxagliptin+metformin and metformin alone groups (p<0.0001).
7 Prosječna promjena vrijednosti HbA1c odnosi se na razliku između skupine koja je primala saksagliptin+metformin i skupine koja je primala samo metformin (p<0,0001).
7 mg per kilogram body weight for children and adolescents not receiving regular blood transfusions.
7 mg po kilogramu tjelesne težine za djecu i adolescente koji ne primaju redovite transfuzije krvi.
7 mg/kg once every 24 hours
7 mg/kg jedanput svaka 24 sata
7 mg/kg once every 24 hours infused over 30 minutes
7 mg/kg jedanput svaka 24 sata infuzijom tijekom 30 minuta
7 mg/kg twice daily
7 mg/kg dva puta na dan
7 ml/m2/day (8 g/m2/day) in patients with a BSA ≥ 1.3 m2
7 ml/m2/dan (8 g/m2/dan) za bolesnike s površinom tijela ≥ 1,3 m2
7 or 21 hard capsules
7 ili 21 tvrdih kapsula
7 OTHER SPECIAL WARNINGS, IF NECESSARY
7 DRUGO(A) POSEBNO(A) UPOZORENJE(A), AKO JE POTREBNO
7 patches
7 flastera
7 patients were analysed for resistance development and all had genotypic and phenotypic data available.
7 pacijenata i svi su imali dostupne genotipske i fenotipske podatke.
7 pouches
Transdermalni
7 pre-filled syringes + 7 alcohol swabs
7 napunjenih štrcaljki + 7 maramica natopljenih alkoholom
7 pre-filled syringes with solvent for parenteral use.
7 napunjenih štrcaljki s otapalom za parenteralnu uporabu.
7 prolonged-release tablets
7 tableta s produljenim oslobađanjem
7 prolonged-release tablets of 0.26 mg
7 tableta s produljenim oslobađanjem od 0,26 mg
7 prolonged-release tablets of 0.52 mg
7 tableta s produljenim oslobađanjem od 0,52 mg
7 prolonged-release tablets of 1.05 mg
7 tableta s produljenim oslobađanjem od 1,05 mg
7 spike of the transparent adapter end straight down through the product vial stopper.
7 ugurajte ravno prema dolje kroz čep bočice s lijekom.
7 sublingual tablets
7 sublingvalnih tableta
7 tablets
7 tableta
7 tablets (PVC/CTFE/alu blisters) 14 tablets (PVC/CTFE/alu blisters) 28 tablets (PVC/CTFE/alu blisters) 49 tablets (PVC/CTFE/alu blisters) 56 tablets (PVC/CTFE/alu blisters) 98 tablets (PVC/CTFE/alu blisters) 7 tablets (PVC/PVDC/alu blisters) 14 tablets (PVC/PVDC/alu blisters) 28 tablets (PVC/PVDC/alu blisters) 49 tablets (PVC/PVDC/alu blisters) 56 tablets (PVC/PVDC/alu blisters) 98 tablets (PVC/PVDC/alu blisters)
7 tableta (PVC/CTFE/alu blisteri) 14 tableta (PVC/CTFE/alu blisteri) 28 tableta (PVC/CTFE/alu blisteri) 49 tableta (PVC/CTFE/alu blisteri) 56 tableta (PVC/CTFE/alu blisteri) 98 tableta (PVC/CTFE/alu blisteri) 7 tableta (PVC/PVDC/alu blisteri) 14 tableta (PVC/PVDC/alu blisteri) 28 tableta (PVC/PVDC/alu blisteri) 49 tableta (PVC/PVDC/alu blisteri) 56 tableta (PVC/PVDC/alu blisteri) 98 tableta (PVC/PVDC/alu blisteri)
7 tablets 10 tablets
7 tableta 10 tableta
7 tablets in blister packs Paper/Aluminium/Nylon/Aluminium/PVC.
7 tableta u papir/aluminij/najlon/aluminij/PVC blister pakiranju .
7 tablets of the lower strength), 28 (14 tablets of the higher strength + 14 tablets of the lower strength) or 56 (28 tablets of the higher strength + 28 tablets of the lower strength) tablets
+ 7 slabijih tableta), 28 (14 jačih tableta + 14 slabijih tableta) ili 56 (28 jačih tableta + 28 slabijih tableta) tableta
7 The incidence of nasal congestion was dose related during ambrisentan therapy.
7 incidencija nazalne kongestije bila je ovisna o dozi tijekom terapije ambrisentanom
7 to 14 mg/kg (0.07 to
7 do 14 mg/kg (0,07
7 to 14 mg/kg (0.07 to
7 do 14 mg/kg (0,07 do